If you have been reading about circadian clock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Some symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgement, drowsiness, shallow breathing, staggering, and, in severe cases, coma or death. The lethal dosage of barbiturates varies greatly with tolerance and from one individual to another. The lethal dose is highly variable among different members of the class, with superpotent barbiturates such as pentobarbital being potentially fatal in considerably lower doses than the low-potency barbiturates such as butalbital. Even in inpatient settings, the development of tolerance is still a problem, as dangerous and unpleasant withdrawal symptoms can result when the drug is stopped after dependence has developed. Tolerance to the anxiolytic and sedative effects of barbiturates tends to develop faster than tolerance to their effects on smooth muscle, respiration, and heart rate, making them generally unsuitable for a long time psychiatric use. Tolerance to the anticonvulsant effects tends to correlate more with tolerance to physiological effects, however, meaning that they are still a viable option for long-term epilepsy treatment. Barbiturates in overdose with other CNS (central nervous system) depressants (e.g. alcohol, opiates, benzodiazepines) are even more dangerous owing to additive CNS and respiratory depressant effects. In the case of benzodiazepines, not only do they have additive effects, barbiturates also increase the binding affinity of the benzodiazepine binding site, leading to exaggerated benzodiazepine effects. (ex.
== History == Lurbinectedin was approved for medical use in the United States in June 2020. Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multi-center open-label, multi-cohort study enrolling 105 participants with metastatic small cell lung cancer who had disease progression on or after platinum-based chemotherapy. Participants received lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity. The trial was conducted at 26 sites in the United States, Great Britain, Belgium, France, Italy, Spain and Czech Republic. The US Food and Drug Administration (FDA) granted the application for lurbinectedin priority review and orphan drug designations and granted the approval of Zepzelca to Pharma Mar S.A. The efficacy of lurbinectedin used in combination with atezolizumab or in combination with atezolizumab/hyaluronidase was evaluated in IMforte (NCT05091567), a randomized, multi-center, open-label trial in participants receiving first-line treatment for extensive-stage small cell lung cancer. In IMforte, 483 participants with extensive-stage small cell lung cancer whose disease had not progressed after completion of four cycles of atezolizumab, carboplatin, and etoposide (induction treatment) were randomized (1:1) to receive either lurbinectedin in combination with atezolizumab administered intravenously or atezolizumab intravenously alone until disease progression or unacceptable toxicity.
=== Anticonvulsants === Although it was previously withdrawn from the market as an appetite suppressant, fenfluramine was reintroduced as an anticonvulsant for treatment of seizures in certain rare forms of epilepsy like Dravet syndrome and Lennox–Gastaut syndrome. Selective serotonin 5-HT2C receptor agonists, like lorcaserin, bexicaserin, and BMB-101, are also being developed for this use.
Sources: en.wikipedia.org
== Organismal involvement == This enzyme is widely distributed and a number of crystal structures have been solved, including in Escherichia coli, Pyrococcus Horikoshii, Thermoplasma acidophil, Homo sapiens, Thermus thermophilus and Mycobacterium tuberculosis. The most extensive structural studies have been done in E. coli.
Big dynorphin is an endogenous opioid peptide of the dynorphin family. It forms when a precursor protein prodynorphin is not fully processed, resulting in a 32-amino acid molecule containing both dynorphin A and dynorphin B sequences. It has the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr. Big dynorphin is a highly efficiacious principal endogenous agonist at the human κ-opioid receptor (KOR). It produces one of the strongest responses at GPR139 receptor among dynorphins. Additionally, it uniquely modulates NMDA receptor and potentiates acid-sensing ion channel 1a (ASIC1a). It plays a role in pain and stress responses. It exhibits both analgesic and pro-nociceptive properties. In mice it modulates memory and learning, and has anxiolytic properties, contributing to homeostatic regulation of opioid signaling in the central nervous system.
Milk production can be induced in transgender women by the use of hormone medication, usually a galactagogue similarly to induced lactation in cisgender women, with domperidone being a common choice. Induced lactation without the use of galactagogues has also been demonstrated in at least two cases using a modified feminizing hormone therapy featuring progesterone and nipple stimulation, with eventual successful production of breast milk. In one case report, a transgender woman was able to produce 7 mL of milk per day with hormone treatment. A different transgender woman was able to produce 8 oz of milk per day achieving "sufficient breast milk volume to be the sole source of nourishment for her child for six weeks." Several studies analyzing milk samples from trans women have found them to contain nutrients within parameters suitable for nursing. A 2018 survey of medical professionals with attending a WPATH event where 34% of the surveyed professionals had met a transgender patient expressing interest in induced lactation, 21% of them knew of providers who facilitated lactation for transgender patients, and 9% had themselves helped trans women induce lactation.
It is also formed by the degradation of precursors such as some fluorotelomers. PFOA is used as a surfactant because it can lower the surface tension of water more than hydrocarbon surfactants while having exceptional stability due to having perfluoroalkyl tail group. The stability of PFOA is desired industrially but is a cause of concern environmentally. The primary manufacturer of perfluorooctanesulfonic acid (PFOS), 3M, began a production phase-out in 2002 in response to concerns expressed by the U.S. Environmental Protection Agency (EPA). Eight other companies agreed to gradually phase out the manufacturing of the chemical by 2015. By 2014, EPA had listed PFOA and perfluorooctanesulfonates (salts of perfluorooctanesulfonic acid, PFOS) as emergent contaminants:
Sources: en.wikipedia.org
The UPMC Rooney Sports Complex is a multipurpose, multisport training, sports science, and sports medical complex located along the shore of the Monongahela River in Pittsburgh and is unique in that it combines training facilities for the University of Pittsburgh football team and the Pittsburgh Steelers NFL team in one location with an academically based sports science and medicine program. The complex consists of four centers which include the Center for Sports Medicine, Sports Training Center, Indoor Training Center, and the Fitness and Conditioning Center.
=== Comparison between conventional and in situ analysis === Conventional analysis Conventionally, monazite is separated from samples by dissolution and chemical methods. Single or fractions of crystals are selected for dating, usually by thermal ionization mass spectrometry (TIMS). That means one age is generated for a single monazite crystal or for a group of crystals. The age information obtained is obviously inconsistent and inaccurate, because even a single monazite crystal contains zones of different ages. Also, mechanical separation for monazite often destroys the associated textural and spatial information in the monazite crystals, which is crucial in interpreting relationships between domains and geological environments. In-situ analysis
== Distribution and habitat == The croaking gourami is native to stillwater habitats including ponds, canals and paddy fields in Java, Borneo, Sumatra, Malaya, Thailand, Laos, Cambodia, and Vietnam. A breeding population is known to exist in a series of drainage ditches in Florida; this population is almost certainly introduced there through the aquarium trade.
25 December The Met Office provisionally confirms the highest daily minimum temperature for Christmas Day on record, at 12.4 °C (54.3 °F). However, a white Christmas is recorded in the Scottish Highlands, with snow falling in Tulloch Bridge and Aviemore. Police are investigating a fire at the constituency office of Mike Freer, the MP for North Finchley and Golders Green, which broke out on Christmas Eve. The Food Standards Agency has issued recall notices for five brands of cheese amid concerns they could contain the E.coli bug. King Charles III delivers his second Christmas message in which he emphasises the "universal" values shared between different religions at a time of "increasingly tragic conflict around the world". 26 December Analysts predict that property prices will fall in 2024 but that the cost of rents will rise. A major study published by the Jama Network indicates that a deficiency in Vitamin D, depression and diabetes are major contributing factors to early onset dementia. A yellow weather warning is issued for heavy rain and high winds ahead of the arrival of Storm Gerrit, expected to cause disruption the following day. 27 December The UK government announces that pint-sized bottles of still and sparkling wine will appear on the shelves of British supermarkets. Storm Gerrit: A major incident is declared after a tornado rips through parts of Greater Manchester, knocking down trees and causing significant damage to properties. No injuries are reported.
=== Enhancing hydrophobic interaction === Okano’s group expanded on their success by using different modifiers to enhance hydrophobicity through the attachment of butyl methacrylate (BMA), a hydrophobic comonomer. For simplification the resultant polymer has been labeled as IBc (isopropylacrylamide butyl methacrylate copolymer). The polymers were synthesized using radical telomerization with varying BMA content. Where pure PNIPAAm was unable to resolve hydrophobic steroids at any temperature, IBc-grafted silica stationary phases were able to resolve steroid peaks with increasingly retarded retention times in correlation to both increased BMA content and increased temperature. They went on to develop a method to separate phenylthiohydantoin(PTH)-amino acids using their IBc stationary phase with a stronger emphasis of implementing environmentally friendly conditions using a purely aqueous phase in HPLC. Another group separated catechins using PNIPAAm.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.